Core Insights - Fudan University has announced procurement intentions for 34 types of scientific instruments, with a total budget of 103 million yuan [2][3] Instrument Procurement Overview - The procurement includes advanced instruments such as: - Electronic Paramagnetic Resonance Spectrometer - Fourier Transform Infrared Spectrometer - Multi-Omics Linear Ion Trap Triple Quadrupole Liquid Chromatography-Mass Spectrometry - 6G Communication Intermediate Frequency Broadband Vector Source - Inductively Coupled Plasma Multiple Reaction Monitoring Mass Spectrometer - Ultra-High Performance Liquid Chromatography Tandem Quadrupole Mass Spectrometry - Multiphoton Microscope - Single-Cell Biochemical Analyzer - Fully Automatic Fourier Transform Infrared Imaging Microsystem - Quadrupole-Time of Flight Liquid Chromatography-Mass Spectrometry - The expected procurement period is from July to December 2025 [3][4][5][6] Instrument Descriptions - **Ultra-High Performance Liquid Chromatography Tandem Quadrupole Mass Spectrometry (UPLC-MS/MS)**: Combines chromatographic separation with mass spectrometric detection, widely used in chemistry, food science, pharmacy, and clinical diagnostics [4] - **Multi-Omics Linear Ion Trap Triple Quadrupole Liquid Chromatography-Mass Spectrometry**: Designed for high-throughput quantitative analysis and high-resolution qualitative identification, particularly suitable for metabolomics, proteomics, and lipidomics [5] - **Multiphoton Microscope**: Utilizes nonlinear optical effects for deep imaging of biological samples, significantly reducing phototoxicity and enhancing penetration depth, essential in modern biomedical research [7] Related Procurement Plans - Fudan University has previously announced procurement intentions with budgets of 110 million yuan and 146 million yuan for various instruments [8] - A detailed procurement list for the instruments intended for 2025 has been compiled [8]

Core Insights - The life sciences instrument sector is experiencing significant capital inflow and technological innovation in 2025, with a notable trend towards domestic substitution [1][2] - The financing activity in the first half of 2025 has surpassed that of the same period in 2024, with a total of approximately 1.5 billion yuan raised across 13 financing events [2] Financing Overview - In the first half of 2025, 13 financing events were completed, totaling around 1.5 billion yuan, with a balanced distribution across various financing rounds: 4 in A round, 4 in B round, 3 in C round, and 2 in angel round [2] - Key financing events include: - Kunpeng Gene: over 100 million yuan in B round [2] - Yinsais: several hundred million yuan in C round [2] - Zhenmai Bio: 280 million yuan in C+ round, the highest amount in the first half [3][2] Sector Analysis - Sequencing and synthetic biology are leading the investment landscape, with sequencing-related companies accounting for over 30% of the financing events [3] - The market for sequencing instruments is expected to maintain a compound annual growth rate of over 20% due to increasing demand for precision medicine and single-cell sequencing [3] Synthetic Biology Financing - Synthetic biology has emerged as a hot investment area since 2024, continuing into 2025, with significant financing amounts [4] - Companies like Yinsais and Lingzhi Technology are focusing on nucleic acid synthesis and DNA synthesis, respectively, aligning with global trends in mRNA technology [4] AI and Advanced Instrumentation - Companies are integrating AI with high-end instrumentation, exemplified by Tianlu Technology's intelligent experimental design tools and Chaowei Jing's multi-photon microscope [5] - This trend indicates a shift towards interdisciplinary innovation, enhancing the competitiveness of domestic instruments [5] Domestic Instrumentation Landscape - Lid Health's substantial angel round financing has drawn attention, positioning the company as a comprehensive supplier of high-end life science instruments [6] - The company aims to consolidate the market by acquiring smaller players, drawing parallels with international leaders like Thermo Fisher [6] Policy and Market Dynamics - The rapid development of domestic life science instruments is driven by supportive policies and growing market demand, particularly in biomedicine and CGT sectors [7] - Despite active financing, domestic manufacturers face challenges such as reliance on imported core components and the need for brand recognition [7] Future Outlook - The life sciences instrument sector is expected to see a shift from broad investment strategies to a more focused approach, favoring companies with high technological barriers and significant domestic substitution potential [8] - The industry is anticipated to produce several "hidden champions" in niche areas within the next 3-5 years, moving towards the high end of the global value chain [8]